Cannara Biotech Inc. (LOVE) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Cannara Biotech, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.896 Good morning and welcome to Canara Biotech's fiscal year Q3 financial results for the 00:00:03.896 -- 00:00:08.022 three and nine months ended May 31st, 2025. 00:00:08.022 -- 00:00:11.526 As a reminder, this presentation is being recorded. 00:00:11.526 -- 00:00:14.911 Following prepared remarks, we will conduct a question and answer session. 00:00:14.911 -- 00:00:19.037 Please submit your questions to investors at canara.ca 00:00:19.037 -- 00:00:24.304 or in the chat option in your browser. Before we begin, please refer to slide 00:00:24.304 -- 00:00:26.647 two and three of our earnings presentation. 00:00:26.647 -- 00:00:31.185 All information today It's subject to our general disclaimers on financial measures and 00:00:31.185 -- 00:00:37.292 forward-looking statements, which are available to be read in detail at cedarplus.ca. 00:00:41.743 -- 00:00:45.450 I will now turn the presentation over to Nicholas Sosiat, Chief Financial Officer at 00:00:45.450 -- 00:00:46.994 Canara Biotech. 00:00:46.994 -- 00:00:51.039 Thank you, Scott. Good morning, everyone, and thank you for joining Canara's earning 00:00:51.039 -- 00:00:55.884 presentation for the fiscal third quarter, ended May 31st, 2025. 00:00:55.884 -- 00:01:01.010 My name is Nicholas Sosiak, CFO of Canara, and as many of you may know, I have been deeply 00:01:01.010 -- 00:01:04.414 involved in every aspect of this company since 2019. 00:01:04.414 -- 00:01:09.540 From cultivation to processing, finance, strategy, construction, sales and marketing, 00:01:09.540 -- 00:01:12.644 product development, you name it, I've had my hands in it. 00:01:12.644 -- 00:01:16.709 Today, it will be my pleasure to provide you with an update on our best quarter since 00:01:16.709 -- 00:01:21.534 the c...